Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. NEJM, June 2014 [online]
Pagani, O., et al.
http://www.nejm.org/doi/pdf/10.1056/NEJMoa1404037
The most effective adjuvant endocrine therapy for premenopausal women with hormone-receptor (estrogen, progesterone, or both)–positive breast cancer is uncertain. Tamoxifen for at least 5 years is a standard of care. Adjuvant suppression of ovarian function (hereafter, ovarian suppression) may be recommended in addition. For postmenopausal women, adjuvant therapy with an aromatase inhibitor, as compared with tamoxifen, improves outcomes.
